Sunshine Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SBFM research report →
Price Chart
About the company
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers.
- CEO
- Steve N. Slilaty
- IPO
- 2022
- Employees
- 50
- HQ
- Fort Lauderdale, FL, US
Get TickerSpark's AI analysis on SBFM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.74M
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.14
- P/B
- 0.02
- EV/EBITDA
- 1.62
- Div Yield
- 0.00%
- Gross Margin
- 29.86%
- Op Margin
- -16.84%
- Net Margin
- -17.45%
- ROE
- -24.51%
- ROIC
- -20.36%
Latest fiscal year · YoY change
- Revenue
- $36.31M+4.1%
- Gross Profit
- $11.92M+11.8%
- Op Income
- $-4,478,782
- Net Income
- $-5,975,352-16.4%
- EPS
- $-288.00+80.3%
- OCF Growth
- +57.5%
- FCF Growth
- +62.9%
- 52W High
- $464.00
- 52W Low
- $2.23
- 50D MA
- $8.45
- 200D MA
- $91.91
- Beta
- 1.35
- RSI (14)
- 27
- Avg Volume
- 301.19K
No earnings-call transcripts are available for SBFM yet.
- Free Float
- 23.4%
- Shares Outstanding
- 2.12M
- Float Shares
- 497.44K
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for SBFM, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Roger WilliamsHouse · TX25 | Buy | Jun 30, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 7, 26 | NATAN DAVID | other | 58,300 |
| Apr 14, 26 | NATAN DAVID | other | 100,000 |
| Jan 13, 25 | Roy Michel | other | 0 |
| Mar 4, 24 | Slilaty Steve N. | buy | 100,000 |
| Feb 8, 24 | Slilaty Steve N. | buy | 20,000 |
| Jan 26, 24 | Beaudoin Marc | other | 0 |
| Nov 30, 22 | Sebaaly Camille | buy | 30,000 |
| Oct 20, 22 | Chamoun Malek | other | 0 |
| Jun 3, 22 | Sebaaly Camille | buy | 25,000 |
| Feb 18, 22 | Slilaty Steve N. | sell | 990,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SBFM coverage
Recent articles, reports, and earnings notes.
No research on SBFM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SBFM report →Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
accessnewswire.com · Oct 22
Sunshine Biopharma, Inc. (NASDAQ:SBFM) Sees Significant Growth in Short Interest
defenseworld.net · Oct 12
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
accessnewswire.com · Oct 9
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
accessnewswire.com · Oct 8
Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know
zacks.com · Sep 24
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
accessnewswire.com · Sep 24
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
accessnewswire.com · Sep 16
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
accessnewswire.com · Aug 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.